JNJ Keeps Climbing. Should You Climb On?

This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.

Johnson & Johnson (JNJ) makes everything from blockbuster cancer drugs to robotic surgical systems. For the past year, the market has been rewarding it handsomely. The stock has climbed 56% in twelve months, outperforming the S&P 500, and now trades near its 52-week high.

The performance has been so strong it puts would-be buyers in a classic bind. The business is clearly firing on multiple cylinders, but with the stock at these levels, is there any room left for a new investor? Or has the price already captured all the good news? The run is real; the open question is whether there is anything left for a buyer at this price.

What’s Fueling the Momentum?

This is not a stock running on fumes. Johnson & Johnson’s momentum, which places it in the top 12% of large U.S. stocks on trend strength, is backed by elite business quality. Its operating margin over the last year was 27%, comfortably ahead of the 18.5% median for the S&P 500.

The power comes from its Innovative Medicine business. Key drugs are posting remarkable growth, with immunology treatment TREMFYA delivering 71% sales growth in the most recent quarter. The foundational multiple myeloma therapy, DARZALEX, continues to expand, growing sales close to 18% to more than $4 billion. Even with biosimilar competition for its older drug STELARA, management noted that excluding it, the company “grew double digits in the quarter.”

New launches are also gaining traction. Management highlighted that since its debut, “more than 10,000 patients have initiated therapy on ICOTYDE,” a new oral treatment for psoriasis. This performance led the company to beat expectations and raise its full-year guidance.

The Market Is Charging a Premium for This Performance

Quality like this rarely comes cheap. A buyer today pays a price-to-earnings multiple of 30.0, a significant premium to the S&P 500 median of 23.7. The market sees the powerful engine and is charging an admission fee for it. For investors who prefer a broader approach, a broad healthcare fund offers exposure to the sector without concentrating on a single name’s valuation.

But the honest catch for JNJ extends beyond its valuation and into the business itself. The MedTech division is showing signs of strain. Management was direct on its latest earnings call, stating that in MedTech, “results were not to our standards in cardiovascular.” Specifically, the Abiomed heart recovery business saw a 2% sales decline, which the company attributed to “pressures on U.S. procedures.” This slowdown in a key growth segment is the primary risk that could stall the stock’s run.

Can New Medicines Outrun a Slowdown in MedTech?

This brings the entire question into focus. Can the explosive growth in pharmaceuticals compensate for the drag from parts of the medical device business? A look back at the stock’s recent history shows signs of this strength building, a dynamic highlighted by a Trefis analysis of the company’s momentum.

The ultimate test for investors sizing up this run is whether the company can deliver on its updated forecast. The number to watch is full-year operational sales growth. Johnson & Johnson now guides for a range of 6.2% to 6.8% for 2026. Hitting that target would prove the engine is still pulling hard enough. Falling short would suggest the MedTech slowdown is a bigger problem than the market currently believes.

For more runs powered by rising forecasts rather than pure sentiment, our Guidance Momentum screen surfaces exactly those setups, daily.

Those drawn to the run but not the single-name risk have another route: a healthcare ETF like XLV owns the whole group. That way no single company’s next surprise decides the outcome.

Winners Take Over Portfolios Quietly

Quality stocks in uptrends are exactly the positions that quietly take over portfolios. A position that has grown large enough to matter is worth sizing deliberately rather than by accident. What a position that size would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.